Superworth

Biodesix BDSX

Medical - Diagnostics & Research, Healthcare
$21.78
−6.34%
Market cap
$229.8M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.2×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$102.9M
+34% on a year ago
Net margin
−27.0%
Free cash flow yield
−8.8%

Biodesix trades at 2.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $102.9M over the last twelve months, up 34% on a year earlier with a −27% net margin.

Charts

Financials

Income statement for BDSX, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$13.5M+22%$14.7M+53%$14.8M+64%$17.9M+51%$18.2M+35%$20.4M+39%$18M+21%$20M+12%$21.8M+20%$28.8M+41%$25.6M+42%$26.9M+34%
R&D$1.9M−35%$1.9M−47%$2M−37%$2.6M−12%$2.5M+31%$2.4M+28%$2.9M+41%$3.3M+28%$3M+18%$2.9M+19%$3.3M+15%$3.1M−4%
SG&A$15.5M+3%$16.3M−2%$20.6M+8%$19.7M+18%$20M+29%$20.2M+24%$20.4M−1%$22.4M+14%$21.7M+9%$23M+14%$24.3M+19%$24.3M+8%
−$7.2M−32%−$6.9M−51%−$11M−33%−$8.2M−25%−$8.6M+20%−$6.6M−3%−$9.1M−17%−$9.7M+18%−$7.1M−18%−$2M−70%−$6.2M−32%−$5.4M−45%
Interest expense$2.4M−22%$2.3M−9%$2.5M+6%$1.9M−20%$2M−15%$1.8M−25%$1.7M−33%$1.9M−2%$2.1M+2%$2.1M+18%$2M+17%$2M+4%
Net income−$10.9M−20%−$9.1M−55%−$13.6M−27%−$10.8M−19%−$10.3M−6%−$8.3M−10%−$11.1M−19%−$11.5M+6%−$8.7M−15%−$4M−52%−$7.8M−30%−$7.3M−37%
−$2.80−59%−$2.00−71%−$2.80−42%−$1.60−53%−$1.40−50%−$1.13−44%−$1.52−46%−$1.56−3%−$1.16−17%−$0.49−57%−$0.81−47%−$0.71−55%
4M+97%4.6M+61%4.9M+25%6.4M+62%7.3M+84%7.3M+59%7.3M+50%7.3M+15%7.5M+3%8.1M+10%9.7M+32%10.3M+40%

EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Biodesix's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BDSXBiodesix$229.8Mn/mn/a2.2×+34%−27.0%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
ELMDElectromed$223.9M20.4×29.0×3.0×+15%15.3%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
CYHCommunity Health Systems$296.2M8.1×4.5×0.0×−8%0.3%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
VMDViemed Healthcare$359.6M26.2×26.2×1.2×+25%4.8%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
Peer median$250.1M13.9×20.5×1.6×+10%11.9%

More on Biodesix

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .